免疫障害に由来する精神神経疾患血液検査薬の基本特許が米国において成立
2018年4月25日に免疫障害に由来する統合失調症/自閉症検査薬開発に必須であるコア技術が、日本に続き米国にて特許として成立いたしました。
この特許取得により、RESVOは、国内よりも大きな医薬品マーケットでもある米国市場への進出を加速してまいります。
【今回成立した米国特許】
Title: Biomarker for Psychiatric and Neurological Disorders
Applicant: RESVO Inc., Tokyo
App/Pub Number：US2016/0131663 A1
PCT Number: PCT/UP2014/057227
RESVOは、本特許技術を基盤技術とし、免疫障害性統合失調症/自閉症をはじめとして難病の包括的ケアの実現を目指しています。また、本技術を活用した受諾検査、周辺技術を活かした共同研究を通じて、精神・神経疾患の新たな治療法の開発に貢献しています。
***
RESVO announces U.S. Patent Issuance of Biomarker for Psychiatric and Neurological Disorders
OTA, Tokyo – May 21, 2018 – RESVO, Inc., a research and development company specialized in the immune activation-associated neurodevelopmental disorders, announced the issuance of U.S. Patent Number PCT/UP2014/057227 for “Biomarker for Psychiatric and Neurological Disorders.” This patent involves the serologic biomarker technologies which is vital for the development of the test agents of psychiatric and neurodevelopmental disorders, following the patent issuance in Japan in August 2017.
“We are pleased to extend the intellectual property protection by the new patent issuance in the U.S. and accelerate the market launch in the U.S., which is significantly larger than Japan,” said Yoshifumi Kobayashi, CEO of RESVO.
About RESVO
RESVO is devoted to developing the core technologies of the serologic biomarkers and aims to realize the comprehensive care for intractable neurodevelopmental disorders such as Schizophrenia and autism. Our mission is to develop new treatment strategies for psychiatric and neurological disorders through the examinations based on our core technologies and joint research with the related technologies.
すべての画像
